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SHORT COMMUNICATION
Dose efficacy study of two schedules of high-dose bolus administration of 
interleukin 2 and interferon alpha in metastatic melanoma
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Summary Forty-three patients with metastatic melanoma were treated with a 5 day (18 patients) and a 3 day 
(25 patients) schedule of high-dose IL-2 11.7 MIU m2 and IFN-a 3 MIU n r  i.v. by bolus administration every 
8 h, repeated every 21 days lor a total of three courses. The 5 day schedule resulted in a high response rate of 
41% (Cl 18-67%), but was accompanied by severe cardiotoxicity (41%) and central nervous system toxicity 
(28%). The 3 day schedule was associated with manageable toxicity, but yielded a moderate response rate of 
20% (Cl 7-43% ).
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The biological agents, interferon alpha (IFN-a) and 
interleukin 2 (IL-2) have shown evidence of activity against 
metastatic melanoma. IFN-a produced objective tumor 
regression in approximately 15% of patients (Creagan et 
al., 1990; Kirkwood, 1991). IL-2, with or without lympho- 
kine-activated killer cells, yielded response rates from 10- 
25% (Rosenberg et al., 1989a; Parkinson et al., 1990; 
Whitehead et al., 1991). With the combination of IL-2 and 
IFN-a the reported response rates varied between 0-44%  
(Rosenberg et al., 1989h; Dillman et al., 1993; Sparano et al., 
1993; Keilholz et al., 1993; Kruit et al., 1995). A phase I II 
study with increasing dose levels of bolus IL-2 and IFN-a 
produced an objective response in 33% of patients 
(Rosenberg et al., 1989h). The highest response rate of 44% 
was reached with a schedule of IL-2 11.7 MIU m 2 and IFN- 
a 3 MIU m 2 three times a day by intravenous bolus 
administration, 5 days per cycle. We performed a phase II 
study with this schedule in order to confirm these results.
Treatment
In part I of the study patients received recombinant IL-2 at a 
dose of 11.7 MIU m-2 (Teceleukin; Hoffman La Roche, 
Nutley, NJ, USA) and recombinant IFN-a at a dose of 3 
MIU m -2 (Roferon-A, Hoffman La Roche, Basle, Switzer­
land), each administered as an intravenous injection over 
15 min, every 8h  on days 1-5. Treatment was repeated 
every 21 days up to a total of three cycles. With this schedule 
we were confronted with severe cardiotoxicity, albeit the first 
3 days of treatment were relatively well tolerated. Therefore, 
we decided to modify the treatment schedule, using the same 
daily dosages of IL-2 and IFN-a, but now for 3 instead of 5 
days.
The World Heath Organization (WHO) criteria were used 
to grade toxicity (WHO, 1979). Treatment was permanently 
discontinued if grade 3 neurotoxicity or cardiovascular 
toxicity occurred. In case of grade 3 hypotension, therapy
continued while giving symptomatic treatment with
Patients and methods
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Corticosteroid administration was not allowed, except in the 
event of life-threatening toxicity.
The first tumour assessment was performed at 8 weeks 
after the start of therapy. Response evaluations were repeated 
every 4 weeks. Response categories were defined according to 
WHO criteria (WHO, 1979). The treatment results were 
analysed on an intent-to-treat basis. The median survival was 
estimated using the Kaplan-Meier method.
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Absolute numbers of lymphocyte subsets and cytotoxic 
activities of peripheral blood mononuclear cells (PBMCs) 
were assessed in each treatment cycle, immediately before 
the first administration and 1 week later. The lymphocyte 
subsets defined by double-staining with CD3 and CD56, 
CD4 and CD8, CD 16 and CD 19 monoclonal antibodies
were assessed by multicolour immunofluorescence and flow
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cytometry as described elsewhere (Gratama et cil., 1996). 
Cytotoxic activities of lymphocytes were determined in 
standard 3 h 51Cr-release assays. The K562 erythromyeloid 
leukaemia cell line and the Daudi Burkitt’s lymphoma cell 
line were used as target cells for the assessment of natural 
killer (NK) and lymphokine-activated killer (LAK) activities 
respectively.
Results
Patient characteristics
Forty-three patients were entered in the study, 18 in part I 
and 25 in part II. The characteristics of the eligible patients 
are summarised in Table I. All eligible patients were 
evaluable for response and toxicity. In the 5 day regimen, 
one patient was ineligible because of unmeasurable disease. 
Two patients had previously been treated with isolated limb 
perfusion and one patient received radiotherapy before study 
entry. In the 3 day regimen, two patients were pretreated with 
adjuvant BCG or poly A -p o ly  U.
Treatment characteristics
Of the 17 patients in part I, nine (53%) received three cycles, 
three (18%) two cycles and five (29%) only one cycle. Eight 
patients were taken off study early; six owing to grade 3 -4  
toxicity, one due to rapidly progressive disease and another 
patient refused further treatment. The actual lymphokine 
doses given during the first, second and third cycle, expressed 
as a percentage of the planned dose, were 85%, 42% and 
30% respectively.
Of the 25 patients in part II, 14 (56%), received three 
cycles, five (20%) two cycles and six (24%) one cycle. The 
lymphokine doses administered were 95%, 71% and 54% of 
the planned dosages respectively. Treatment was discontinued 
in one patient after only one single cytokine infusion owing 
to grade 3 toxicity. He was considered a treatment failure.
Treatment results
Table II shows the results at response and survival. With the 
5 day schedule the overall response rate was 41% (95%
Table I Patient characteristics
Part I  Part I I
Evaluable patients 17 25
Age
Median 48 41
Range 29-61 20-69
Sex
Male 9 (53%) 16 (64%)
Female 8 (47 % ) 9 (36%)
Performance status (Karnoisky)
Median 90 90
Range 80-100 80-100
Prior therapy
Surgery 17 (100%) 25 (100%
Immunotherapy 2 (8%)
Chemotherapy 2 (12%) 0
Radiotherapy 1 (6%) 0
Distribution of metastatic sites
Lung 9 (53%) 10 (40%)
Lymph nodes 7 (41 %) 17 (68%)
Subcutaneous 6 (35%) 12 (48 % )
Liver 6 (35%) 9 (36%)
Other (adrenal, pancreas, bone) 8 (47 % ) 9 (36%)
Number of metastatic sites
1 6 (35%) 7 (28 % )
2 4 (24%) 7 (28%)
3 4 (24%) 7 (28%)
4 2 (12%) 4 ( 16 % )
5 1 (6%)
Tabic II Response to treatment
Part I Part II
Evaluable patients 17 25
Complete response (CR) 2 (12%) 0
Partial response (PR) 5 (29 % ) 5 (20%)
Overall response rate 41% 20%
Stable disease (SD) 3 (18%) 4 (26%)
Progressive disease (PD) 7 (41%) 16 (64%)
Median duration of response (months) 8.6 6.6
(range) (2.0-37.5) (3.9-9.9)
Median time to progression (months) 3.2 2.0
(range) (0.7-37.5) (0.5-9.9)
Median survival (months) 10.2 6.8
(range) (2.6-37.5) (0.9-24 + )
confidence interval 18-67%), including two 
responses (CRs). The overall survival was 10.2 months 
(range 2.6-37.5 months). With the 3 day schedule the 
overall response rate was 20% (95% confidence interval 7 -  
43%). No CRs occurred. The overall survival was 6.8 months
(range 0 .9 -2 4 +  months).
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Toxicitv
The adverse effects are shown in Table III. With the 5 day 
schedule a high incidence of severe cardiac toxicity occurred. 
Seven patients (41%) experienced cardiac adverse events; 
cardiomyopathy in four, acute cardiac arrest, myocardial
953
Table III Adverse events
Part 1 Part II
Adverse event
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Grade I¡2 (Vo) Grade 314 ( % )
Fever 12 88 52 48
Skin rash 76 0 64 0
Nausea/vomiting 76 18 40 52
Diarrhoea 53 35 48 44
Malaise 24 76 40 56
Weight gain 35 0 16 4
Hypotension 41 53 60 32
Cardiac 6 35 0 0
Dyspnoea 53 24 28 8
Neuropsychiatrie 41 29 32 4
Oliguria 18 18 20 12
Creatinine 47 0 12 0
Alkaline phosphatase 76 6 56 4
Bilirubin 47 12 16 12
Transaminases 47 53 60 24
Anaemia 53 0 36 8
Thrombocytopenia 41 6 48 0
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Figure I Median absolute numbers of CD56 *, 3 (a), CD3 1 (b), CD4 1 (c) and CDS * (d) lymphocytes in patients treated in the 5 
day schedule (□ )  and in the 3 day schedule (■ ) . Logarithmic scales have been used for the vertical axes in order to compress the
figure. Vertical bars represent confidence limits as defined by the 5th and 95th percentile of each group. The areas between the 
horizontal lines represent the normal range of the different lymphocyte subsets as defined by the 5th and 95th percentiles of healthy 
control persons.
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infarction and negative T-waves in one patient each. The 
details of these patients have been reported elsewhere (Kruit 
et al., 1994). No cardiotoxicity was observed in the 3 day 
regimen.
Two-thirds of patients in the 5 day regimen suffered from 
neuropsychiatrie disturbances such as agitation, disorienta­
tion, confusion and overt psychosis. With the 3-day regimen 
neuropsychiatrie side-effects were encountered in about one- 
third of patients and were mild in most cases. Neurotoxicity 
completely resolved in all patients.
I mm un ologi cal mon i to ring
Before therapy the absolute numbers of NK lymphocytes 
(CD56 + 3~ and CD16 + ), T lymphocytes (CD3 + ), helper/
inducer T lymphocytes (CD4V), cytotoxic/suppressor T 
lymphocytes (CD8 + ) and B lymphocytes (CD191) were The response rate and survival duration of the 3 day schedule 
within the normal range. During therapy, the CD56 1 3", were in the same range as observed in other studies of IL-2 
CD3+ and CD8 ' lymphocyte counts gradually increased 
above normal, whereas the C D 41 and CD19+ remained
The second severe toxicity of the 5-day regimen consisted 
of neuropsychiatric disturbances. Evidence from earlier 
studies showed that the frequency and severity of these 
side-effects are dose dependent (Denicoff et al., 1987; Dillman 
et al., 1993; Sparano et al., 1993; Keilholz et al., 1993; Atkins 
et a l ,  1993). The NCI investigators observed neurotoxicity 
including coma in 54% of patients (Marineóla et al., 1995).
Thus, the promising results on response were accompanied 
by unacceptable toxicities. In an attempt to maintain the high 
anti-tumour activity and to reduce the side-effects, we 
shortened the treatment duration in the second part of the 
study from 5 to 3 days. Indeed, the 3 day schedule was 
accompanied by acceptable toxicity, however, the response 
rate dropped to 20%. A direct comparison between the two 
schedules is difficult, because it was not a randomised study 
and the confidence intervals showed considerable overlap.
and IFN-a in melanoma (Dillman et al., 1993; Sparano et a l,  
1993; Kruit et a l ,  1995). In a recent progress report the NCI 
within the normal range (Figure 1). The number of investigators observed a similar decrease in treatment results 
lymphocytes after each treatment cycle (rebound lymphocy­
tosis) reached a higher value in the 5-day study (Figure 1, 
open symbols) compared with the 3-day study (closed 
symbols). NK and LAK cytotoxic activities of PBMCs 
remained within the normal range in both parts of the 
study, with a large variation between patients (data not 
shown). There was no relationship between tumour response 
and immune parameters.
Discussion
From an earlier performed dose-escalating study of bolus IL-2 
and IFN-a we selected the dosage schedule with the highest 
response rate. This treatment schedule resulted in a 41% 
response rate (95% Cl 18-67%), which is identical to the 
results reported by the NCI investigators (Rosenberg et al., 
1989b).
We observed a high incidence of severe cardiotoxicity. 
Although myocardial toxicity was not so frequently 
encountered in the NCI study as here, several cases of 
myocardial infarction and elevation of cardiac enzyme levels 
in 15% of treatment courses were reported (Rosenberg et al., 
1989/?; Marineóla et al., 1995). Also other recent literature 
indicates that high-dose IL-2 regimens bear a high risk of 
severe cardiotoxicity (Sznol et al., 1992; Atkins et al., 1993; 
Fossa el al., 1993).
after modification of the treatment schedule (one instead of 
three IFN-a administrations per day), made necessary by the 
encountered toxicity (Marineóla et al., 1995). In general the 
response rates and survival data of combined therapy of IL-2 
and IFN-a in patients with metastatic melanoma appeared 
not to be superior to treatment with IL-2 alone and IL-2 in 
combination with lymphokine-activated killer cells (Bar et al., 
1990; Dutcher et al., 1991; Rosenberg et al., 1992, 1994; 
Sparano et al., 1993; Marineóla et a i ,  1995).
In summary, the combination of IL-2 and IFN-a has not 
meaningfully improved the clinical results that may be 
obtained with IL-2 alone. Based on the possibly additive or 
synergistic effects between cytotoxic agents and cytokines, 
biochemotherapy may be an important new treatment 
modality. Combinations of biological response modifiers 
and cytostatics have produced encouraging response rates 
(Richards et al., 1992; Khayat et al., 1993; Legha et al., 
1993).
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